Latest Clinical research Stories
FORT WASHINGTON, Pa. and TOKYO, March 27, 2013 /PRNewswire/ -- ReSearch Pharmaceutical Services Inc. ("RPS"), a leading global contract research organization (CRO), and Asklep Inc. ("Asklep"), one of Japan's largest CROs, today announced the creation of a Joint Venture Company (JVC) to deliver leading-edge R&D outsourcing solutions in Japan to the biopharmaceutical and medical device industries. The exclusive RPS-Asklep collaboration will leverage RPS' proprietary structures...
Among patients with the lung disorder non-cystic fibrosis bronchiectasis, treatment with the antibiotic azithromycin resulted in improvement in symptoms but also increased the risk of antibiotic resistance, according to a study appearing in the March 27 issue of JAMA. Bronchiectasis is characterized by abnormal widening of the bronchi (air tubes that branch deep into the lungs) and can cause recurrent lung infections, a disabling cough, shortness of breath, and coughing up blood. "If...
Although chelation therapy with the drug disodium EDTA has been used for many years with limited evidence of efficacy for the treatment of coronary disease, a randomized trial that included patients with a prior heart attack found that use of a chelation regimen modestly reduced the risk of a composite of adverse cardiovascular outcomes, but the findings do not support the routine use of chelation therapy for treatment of patients who have had a heart attack, according to a study in the March...
Confirming Position as "Best in Determining the Value of Healthcare" LOS ANGELES, March 27, 2013 /PRNewswire/ -- Health economics and policy authority Precision Health Economics (PHE) announced today it has added three additional scientific leaders to its renowned stable of experts. The new principal consultants are preeminent researchers and educators representing the most notable institutions in health economics and health policy; they will contribute to the knowledge base and...
Quarterly Update Conference Call and Webcast Today at 4:30 p.m. ET CASTLE ROCK, Colo., March 26, 2013 /PRNewswire/ -- Venaxis, Inc. (Nasdaq: APPY), an in vitro diagnostic company focused on obtaining FDA clearance and commercializing its rapid, protein biomarker-based appendicitis test, APPY1, today provided an update on its clinical and commercial activities. The Company continues to enroll patients into its ongoing pivotal U.S. clinical study of APPY1, as well as make...
Company to showcase its entire lineup of innovative EDC / eClinical solutions MINNETONKA, Minn., March 26, 2013 /PRNewswire/ -- MedNet Solutions, a global life sciences technology company specializing in clinical study management systems, is pleased to announce its active participation in several upcoming clinical research events during the month of April. MedNet representatives will be providing demonstrations of the company's full lineup of flexible, practical and...
Panels will advise PCORI on research priorities and patient engagement efforts WASHINGTON, March 26, 2013 /PRNewswire-USNewswire/ -- The Patient-Centered Outcomes Research Institute (PCORI) Board of Governors today approved 84 people with a broad range of expertise to serve on PCORI's first four multi-stakeholder advisory panels. The panels will advise PCORI on critical research questions for possible funding and how to ensure that PCORI's work remains patient centered. Each panel...
Marie-Paul Lachaud, D.V.M., to Expand European Operations KANSAS CITY, Kan. and BOSTON, March 26, 2013 /PRNewswire/ -- Aratana Therapeutics, Inc., a biopharmaceutical company focused on licensing, developing and commercializing innovative prescription medications for cats and dogs (companion animals), today announced it has expanded its relationship with Marie-Paul Lachaud, DVM, as a consultant to the company who will lead drug evaluation and development in Europe. Dr. Lachaud is...
AUSTIN, Texas, March 26, 2013 /PRNewswire/ -- XBiotech, a privately held biotechnology company, announced the incorporation of its wholly owned Japanese subsidiary, XBiotech Japan KK. The creation of the Japanese Company is reportedly the first step in XBiotech's strategy to expand its clinical operations and ultimately product reach into the unique Japanese market place. "XBiotech is committed to availing its drug development technologies to serve unmet medical need in Japan," said...
ROCKVILLE, Md., March 26, 2013 /PRNewswire-USNewswire/ -- Accelovance, Inc., a Maryland based contract research organization (CRO), was nominated for the 2013 ViE "Best CRO" Award for the sixth year in a row and is a confirmed finalist in this award category. Therapeutically focused on vaccines, infectious disease, immunology and oncology, Accelovance was a recipient of the award, as determined by an international panel of independent judges, previously in 2009, 2010 and 2011. The...
